NEOVAXSYN INC

AMES, IA · Biotech · Private

Gold nanoparticle-based vaccine delivery platform targeting HIV-1 fusion peptide to induce broadly neutralizing antibodies

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
AMES, IA
Total capital
$4.1M
Federal grants
$897K
3 awards · 2022–2023
Rank in peer group#39 of 392
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$3.2M
5 awards · Health and Human S
Rank in Biotech#106 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20202021202220232024FEDERAL ↑EQUITY ↓Cumulative $3.8M$300K$300K$300K$300K$2M$300K
20202021202220232024FEDERAL ↑EQUITY ↓Cumulative $3.8M$300K$300K$300K$2M

Latest events

  • Federal contractHealth and Human S · Development Of A Next-generation Immunoprevention Platform Against HIV-1$300K
  • Federal contractHealth and Human S · Nanovaccine For Eliciting Bnabs Against HIV-1$2M
  • Federal grantHealth and Human S · Phase I · Induction of bnAbs against HIV-1 gp41.$300K
  • Federal grantHealth and Human S · Phase I · Induction of bnAbs against HIV-1 gp41.$297K
  • Federal contractHealth and Human S · SBIR Phase I$300K
  • Federal contractHealth and Human S · The Contractor Shall Utilize Nanoparticles To Deliver The Mper-based Immunogens To Elicit Bnabs Against The Mper Of HIV-1 GP41 To Develop A Protective Vaccine Against The Virus.$300K
  • Federal contractHealth and Human S · The Objective Of This Contract Is To Utilize Gold Nanoparticles (gnp) To Elicit Broadly Neutralizing Antibodies (bnabs) Against The Fusion Peptide (fp) Of HIV-1 GP41 To Develop A Protective Vaccine Against The Virus.$300K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grants#39 · top 10%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • DNASTAR, INC.Similar federal contract value in Biotech · $3.4M in contracts
  • NOVOMEDIX LLCSimilar federal contract value in Biotech · $3.3M in contracts
  • SynthegoSimilar federal contract value in Biotech · $3.2M in contracts
  • BOLDER BIOTECHNOLOGY INCSimilar federal contract value in Biotech · $3.1M in contracts
  • BIOMATRICA, INC.Similar federal contract value in Biotech · $3M in contracts
  • APOGEE BIOTECHNOLOGY CORPORATIONSimilar federal contract value in Biotech · $3M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .